These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21084794)

  • 1. Denosumab for the management of postmenopausal osteoporosis.
    Singer A; Grauer A
    Postgrad Med; 2010 Nov; 122(6):176-87. PubMed ID: 21084794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
    Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
    J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on denosumab in postmenopausal osteoporosis.
    Moen MD; Keam SJ
    BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB; Pathak R
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
    Törring O
    Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
    [No Abstract]   [Full Text] [Related]  

  • 16. Denosumab: recent update in postmenopausal osteoporosis.
    Silva I; Branco JC
    Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab for treatment of postmenopausal osteoporosis.
    Chitre M; Shechter D; Grauer A
    Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
    Harris KB; Nealy KL; Jackson DJ; Thornton PL
    J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.